unknown
Stage
3
Investors
About
Ethris is a German biotechnology company developing mRNA-based therapeutics and vaccines using proprietary SNIM® RNA and SNaP LNP® delivery platforms. Its pipeline focuses on pulmonary indications such as asthma and rare lung diseases and on enabling thermostable, multi-route lipid nanoparticle delivery.
Explore Ethris's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.